<DOC>
	<DOCNO>NCT00800293</DOCNO>
	<brief_summary>The purpose study compare relative vasoconstrictive effect test reference topical augment betamethasone dipropionate augment 0.05 % cream healthy , female subject .</brief_summary>
	<brief_title>Randomized Study Compare Bioavailability Two Augmented Betamethasone Dipropionate 0.05 % Topical Creams</brief_title>
	<detailed_description />
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>Nontobaccousing female subject , 18 50 year age Demonstrated blanch response Reference Drug ( augment betamethasone dipropionate ) Cream 0.05 % Weight within + 20 % normal height weight body frame Good health determine lack clinically significant abnormality medical history clinical assessment , judge Investigator Signed date informed consent form meet criteria current FDA regulation History allergy systemic topical corticosteroid Presence skin condition coloration would interfere placement test site response assessment skin blanch Presence medical condition require regular treatment prescription drug Drug alcohol addiction require treatment past 12 month prior dose Use dermatological drug therapy flexor surface forearm within 30 day dose Use tobacco product 30 day prior study dose Receipt drug part research study within 30 day prior study dose Pregnant lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>betamethasone dipropionate</keyword>
	<keyword>Bioequivalency</keyword>
</DOC>